News Release

2022.10.28 Research and Development
Notification of the Results of the Phase III Clinical Study of HP-5000 for Osteoarthritis Pain of the Knee in the U.S. (Pain Relief and Anti-Inflammatory Patch)
2022.10.12 lR Information
FY02/2023 Q2 Results Earnings Release Presentation
2022.07.07 lR Information
FY02/2023 Q1 Results Earnings Release Presentation
2022.06.20 Ethical Drugs
Notification of approval for manufacturing and marketing approval of the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU® Tapes (Transdermal, pain treatment NSAID patch, development code: HP-3150) in Japan Hisamitsu
2022.05.26 Management and Personnel
Executive Appointments
2022.05.18 Other
Salonpas® Named the World’s No.1 OTC Topical Analgesic Patch Brand for the Sixth Consecutive Year
2022.04.21 Research and Development
Notification of application for manufacturing and marketing approval of HP-5070 (primary palmar hyperhidrosis treatment drug) in Japan
2022.04.07 Other
Notice regarding humanitarian support for Ukraine
2022.04.07 Management and Personnel
Executive Appointments
2022.04.07 lR Information
FY02/2022 Q4 Results Earnings Release Presentation
2022.03.31 Other
Acquisition of Shares of AYM HD
2022.03.23 lR Information
Notice regarding Revision of Earnings Forecast
2022.03.23 Subsidiaries and Affiliated Companies
Noven Pharmaceuticals, Inc. press release : FDA Approves Once-Daily XELSTRYM™ (dextroamphetamine) Transdermal System, CII, for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients 6 Years and Older
2022.01.14 lR Information
Notice regarding Results and Completion of Acquisition of Treasury Shares
2022.01.13 lR Information
FY02/2022 Q3 Results Earnings Release Presentation

PAGETOP